Medtronic/$MDT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Medtronic
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, surgical robots, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
- Ticker
- $MDT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 95,000
- Headquarters
- Galway, Ireland
- Website
- www.medtronic.com
Medtronic Metrics
BasicAdvanced
$128B
25.83
$4.06
0.57
$2.86
2.75%
Price and volume
Market cap
$128B
Beta
0.57
52-week high
$106.33
52-week low
$73.31
Average daily volume
26M
Dividend rate
$2.86
Financial strength
Current ratio
2.067
Quick ratio
1.286
Long term debt to equity
0.504
Total debt to equity
0.582
Dividend payout ratio (TTM)
69.78%
Interest coverage (TTM)
10.41%
Profitability
EBITDA (TTM)
10,404
Gross margin (TTM)
65.28%
Net profit margin (TTM)
13.93%
Operating margin (TTM)
20.21%
Effective tax rate (TTM)
20.19%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
5.12%
Return on equity (TTM)
10.65%
Valuation
Price to earnings (TTM)
25.826
Price to revenue (TTM)
3.578
Price to book
2.67
Price to tangible book (TTM)
-41.04
Price to free cash flow (TTM)
21.907
Free cash flow yield (TTM)
4.56%
Free cash flow per share (TTM)
4.786
Dividend yield (TTM)
2.73%
Forward dividend yield
2.75%
Growth
Revenue change (TTM)
9.77%
Earnings per share change (TTM)
12.12%
3-year revenue growth (CAGR)
5.96%
10-year revenue growth (CAGR)
2.71%
3-year earnings per share growth (CAGR)
14.42%
10-year earnings per share growth (CAGR)
4.68%
3-year dividend per share growth (CAGR)
1.44%
10-year dividend per share growth (CAGR)
6.14%
What the Analysts think about Medtronic
Analyst ratings (Buy, Hold, Sell) for Medtronic stock.
Analyst projections of the future price of Medtronic stock.
Bulls say / Bears say
Medtronic beat Q1 expectations and raised its FY27 organic revenue growth outlook to 7.25%–7.75%, with growth across all major portfolios. That gives the recovery a broader base than a single-product rebound. (Medtronic)
Cardiac Ablation Solutions grew 88% in Q1, giving Medtronic a powerful growth engine in a large cardiovascular business. Continued uptake could help sustain momentum beyond its more mature device lines. (Medtronic)
Q1’s 13.7% growth was flattered by an extra reporting week that contributed about $570 million. The underlying pace may be less striking, with Q2 organic growth guidance of about 6%. (Yahoo Finance)
A US jury awarded Applied Medical $382 million in an antitrust case; the damages are subject to trebling, and the plaintiff is also seeking an injunction that could constrain sales practices. Medtronic plans to appeal. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Medtronic Financial Performance
Revenues and expenses
Medtronic Earnings Performance
Company profitability
Upcoming events
No upcoming events
Medtronic News
AllArticlesVideos
These 12 stocks are good bets to beat the 10-year Treasury over the next decade
Market Watch2 days ago
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
MarketBeat3 weeks ago
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga4 weeks ago
Funds containing Medtronic
AllUSDEURGBP
Fund name | Fund size | $MDT weighting |
|---|---|---|
Invesco S&P 500 High Dividend Low Volatility£HDLG | $456M | 2.09% |
Invesco S&P 500 High Dividend Low Volatility$HDLV | $456M | 2.09% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 1.90% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 1.90% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.87% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.